FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566765736> ?p ?o ?g. }

• W1566765736 endingPage "265" @default.
• W1566765736 startingPage "265" @default.
• W1566765736 abstract "Purpose: Acromegaly is a rarely diagnosed condition with potentially serious complications including accelerated heart disease and reduced survival. After a mean interval of nearly 9 years from onset of disease, a significant proportion of patients are diagnosed with invasive adenomas precluding complete surgical resection. Furthermore, strict normalization of the growth hormone (GH) target insulin-like growth factor I (IGF-I) cannot always be achieved by adjunctive medical therapy with somatostatin analogues. Here we report the results of a Canadian multi-centre study open-label, dose-titrated long-term study examining safety and efficacy outcomes of a growth hormone receptor antagonist, pegvisomant in 19 patients with refractory acromegaly. Methods: Previously pegvisomant-treated and treatment-naïve refractory acromegalic patients at least 18 yr of age were eligible (n=19). Patients received open-label daily subcutaneous injections of pegvisomant adjusted according to IGF-I levels. Safety and IGF-I levels were assessed every 4 to 6 wk. Baseline and follow-up visits at 3-month intervals also included administration of the Signs and Symptoms of Acromegaly Questionnaire. This study is registered with ClinicalTrials.gov, NCT00151437. Results: We show that, in escalating doses, pegvisomant results in age-adjusted normalization of IGF-I in nearly all such patients. This IGF-I normalization occurred early on and was maintained throughout the study period of 27 months (IGF-I standard deviation score (SDS), mean ± SE: 1.66 ± 0.36, P=0.0003 vs baseline), with a nadir at 18 months (IGF-I SDS, mean ± SE: 1.50 ± 0.38, P=0.0010 vs baseline). IGF-I control was also accompanied by measurable improvements in disease-associated symptoms and without radiographic evidence of pituitary tumour progression. Overall, the safety profile of pegvisomant therapy in this patient population was found to be satisfactory and suitable for a long-term treatment. Conclusion: Our findings provide support for the long-term safety and efficacy of the GH receptor antagonist pegvisomant in achieving IGF-I control in patients with refractory acromegaly." @default.
• W1566765736 created "2016-06-24" @default.
• W1566765736 creator A5001974881 @default.
• W1566765736 creator A5047470812 @default.
• W1566765736 creator A5062732118 @default.
• W1566765736 creator A5066447916 @default.
• W1566765736 creator A5087117328 @default.
• W1566765736 date "2009-12-01" @default.
• W1566765736 modified "2023-09-26" @default.
• W1566765736 title "A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly" @default.
• W1566765736 cites W114877357 @default.
• W1566765736 cites W1982178657 @default.
• W1566765736 cites W1990260162 @default.
• W1566765736 cites W1990309327 @default.
• W1566765736 cites W2000449314 @default.
• W1566765736 cites W2006689584 @default.
• W1566765736 cites W2006939675 @default.
• W1566765736 cites W2014729851 @default.
• W1566765736 cites W2017091398 @default.
• W1566765736 cites W2038453981 @default.
• W1566765736 cites W2050515584 @default.
• W1566765736 cites W2061834810 @default.
• W1566765736 cites W2082370342 @default.
• W1566765736 cites W2099181842 @default.
• W1566765736 cites W2100615084 @default.
• W1566765736 cites W2107594567 @default.
• W1566765736 cites W2113464653 @default.
• W1566765736 cites W2117270119 @default.
• W1566765736 cites W2120902410 @default.
• W1566765736 cites W2134378936 @default.
• W1566765736 cites W2143791513 @default.
• W1566765736 cites W2147795491 @default.
• W1566765736 cites W2152997319 @default.
• W1566765736 cites W2153200944 @default.
• W1566765736 cites W2160989555 @default.
• W1566765736 cites W2312864911 @default.
• W1566765736 cites W613303234 @default.
• W1566765736 cites W98681037 @default.
• W1566765736 doi "https://doi.org/10.25011/cim.v32i6.10662" @default.
• W1566765736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20003832" @default.
• W1566765736 hasPublicationYear "2009" @default.
• W1566765736 type Work @default.
• W1566765736 sameAs 1566765736 @default.
• W1566765736 citedByCount "6" @default.
• W1566765736 countsByYear W15667657362013 @default.
• W1566765736 countsByYear W15667657362015 @default.
• W1566765736 countsByYear W15667657362017 @default.
• W1566765736 countsByYear W15667657362020 @default.
• W1566765736 crossrefType "journal-article" @default.
• W1566765736 hasAuthorship W1566765736A5001974881 @default.
• W1566765736 hasAuthorship W1566765736A5047470812 @default.
• W1566765736 hasAuthorship W1566765736A5062732118 @default.
• W1566765736 hasAuthorship W1566765736A5066447916 @default.
• W1566765736 hasAuthorship W1566765736A5087117328 @default.
• W1566765736 hasBestOaLocation W15667657361 @default.
• W1566765736 hasConcept C121332964 @default.
• W1566765736 hasConcept C126322002 @default.
• W1566765736 hasConcept C134018914 @default.
• W1566765736 hasConcept C141071460 @default.
• W1566765736 hasConcept C142424586 @default.
• W1566765736 hasConcept C2777433750 @default.
• W1566765736 hasConcept C2778886798 @default.
• W1566765736 hasConcept C2984496839 @default.
• W1566765736 hasConcept C71315377 @default.
• W1566765736 hasConcept C71924100 @default.
• W1566765736 hasConcept C87355193 @default.
• W1566765736 hasConcept C90924648 @default.
• W1566765736 hasConceptScore W1566765736C121332964 @default.
• W1566765736 hasConceptScore W1566765736C126322002 @default.
• W1566765736 hasConceptScore W1566765736C134018914 @default.
• W1566765736 hasConceptScore W1566765736C141071460 @default.
• W1566765736 hasConceptScore W1566765736C142424586 @default.
• W1566765736 hasConceptScore W1566765736C2777433750 @default.
• W1566765736 hasConceptScore W1566765736C2778886798 @default.
• W1566765736 hasConceptScore W1566765736C2984496839 @default.
• W1566765736 hasConceptScore W1566765736C71315377 @default.
• W1566765736 hasConceptScore W1566765736C71924100 @default.
• W1566765736 hasConceptScore W1566765736C87355193 @default.
• W1566765736 hasConceptScore W1566765736C90924648 @default.
• W1566765736 hasIssue "6" @default.
• W1566765736 hasLocation W15667657361 @default.
• W1566765736 hasLocation W15667657362 @default.
• W1566765736 hasOpenAccess W1566765736 @default.
• W1566765736 hasPrimaryLocation W15667657361 @default.
• W1566765736 hasVolume "32" @default.
• W1566765736 isParatext "false" @default.
• W1566765736 isRetracted "false" @default.
• W1566765736 magId "1566765736" @default.
• W1566765736 workType "article" @default.